BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 17295644)

  • 21. Combined evaluation of CK5/6, ER, p63, and MUC3 for distinguishing breast intraductal papilloma from ductal carcinoma in situ.
    Furuya C; Kawano H; Yamanouchi T; Oga A; Ueda J; Takahashi M
    Pathol Int; 2012 Jun; 62(6):381-90. PubMed ID: 22612506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adenomyoepithelial tumours and myoepithelial carcinomas of the breast--a spectrum of monophasic and biphasic tumours dominated by immature myoepithelial cells.
    Hungermann D; Buerger H; Oehlschlegel C; Herbst H; Boecker W
    BMC Cancer; 2005 Jul; 5():92. PubMed ID: 16050957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p63 expression in solid cell nests of the thyroid: further evidence for a stem cell origin.
    Reis-Filho JS; Preto A; Soares P; Ricardo S; Cameselle-Teijeiro J; Sobrinho-Simões M
    Mod Pathol; 2003 Jan; 16(1):43-8. PubMed ID: 12527712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibodies targeting p63 react specifically in the cytoplasm of breast epithelial cells exhibiting secretory differentiation.
    Bratthauer GL; Saenger JS; Strauss BL
    Histopathology; 2005 Dec; 47(6):611-6. PubMed ID: 16324199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myoepithelial cell cocktail (p63+SMA) for the evaluation of sclerosing breast lesions.
    Pavlakis K; Zoubouli C; Liakakos T; Messini I; Keramopoullos A; Athanassiadou S; Kafousi M; Stathopoulos EN
    Breast; 2006 Dec; 15(6):705-12. PubMed ID: 16384708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Usefulness of immunohistochemistry for differential diagnosis between benign and malignant breast lesions.
    Moriya T; Kanomata N; Kozuka Y; Fukumoto M; Iwachido N; Hata S; Takahashi Y; Miura H; Ishida K; Watanabe M
    Breast Cancer; 2009; 16(3):173-8. PubMed ID: 19475479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Observer variability in the histopathological reporting of core biopsies of papillary breast lesions is reduced by the use of immunohistochemistry for CK5/6, calponin and p63.
    Douglas-Jones A; Shah V; Morgan J; Dallimore N; Rashid M
    Histopathology; 2005 Aug; 47(2):202-8. PubMed ID: 16045782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Papillary lesions of the breast.
    Ibarra JA
    Breast J; 2006; 12(3):237-51. PubMed ID: 16684322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Morphogenesis of the papillary lesions of the breast: phenotypic observation.
    Rakha EA
    J Clin Pathol; 2016 Jan; 69(1):64-9. PubMed ID: 26251523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intracystic papillary carcinomas of the breast: a reevaluation using a panel of myoepithelial cell markers.
    Collins LC; Carlo VP; Hwang H; Barry TS; Gown AM; Schnitt SJ
    Am J Surg Pathol; 2006 Aug; 30(8):1002-7. PubMed ID: 16861972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of p63 and CD10 in the differential diagnosis of papillary neoplasms of the breast.
    de Moraes Schenka NG; Schenka AA; de Souza Queiroz L; de Almeida Matsura M; Vassallo J; Alvarenga M
    Breast J; 2008; 14(1):68-75. PubMed ID: 18086274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular evidence for progression of microglandular adenosis (MGA) to invasive carcinoma.
    Shin SJ; Simpson PT; Da Silva L; Jayanthan J; Reid L; Lakhani SR; Rosen PP
    Am J Surg Pathol; 2009 Apr; 33(4):496-504. PubMed ID: 19047897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distribution of p63, a novel myoepithelial marker, in fine-needle aspiration biopsies of the breast: an analysis of 82 samples.
    Reis-Filho JS; Milanezi F; Amendoeira I; Albergaria A; Schmitt FC
    Cancer; 2003 Jun; 99(3):172-9. PubMed ID: 12811858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers.
    Tang P; Wang X; Schiffhauer L; Wang J; Bourne P; Yang Q; Quinn A; Hajdu SI
    Ann Clin Lab Sci; 2006; 36(1):16-22. PubMed ID: 16501232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Papillary lesions of the breast: a review.
    Mulligan AM; O'Malley FP
    Adv Anat Pathol; 2007 Mar; 14(2):108-19. PubMed ID: 17471117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Availability of CD10 immunohistochemistry as a marker of breast myoepithelial cells on paraffin sections.
    Moritani S; Kushima R; Sugihara H; Bamba M; Kobayashi TK; Hattori T
    Mod Pathol; 2002 Apr; 15(4):397-405. PubMed ID: 11950913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of p63 in cutaneous metastases.
    Kanitakis J; Chouvet B
    Am J Clin Pathol; 2007 Nov; 128(5):753-8. PubMed ID: 17951196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Histopathological diagnosis of papillary lesion of the breast].
    Akiyama F; Sakamoto G
    Gan To Kagaku Ryoho; 1995 Apr; 22 Suppl 1():32-5. PubMed ID: 7747989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Electron microscopy of intraductal papilloma of the breast. Ultrastructural comparison of papillary carcinoma with normal mammary large duct.
    Tsuchiya S; Takayama S; Higashi Y
    Acta Pathol Jpn; 1983 Jan; 33(1):97-112. PubMed ID: 6301211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. False-positives in fine-needle aspiration cytology of breast disease can be reduced with p63 immunostaining--a preliminary report.
    Nagao T; Bando Y; Sasa M; Morimoto T; Sano N; Hirose T; Tangoku A
    Anticancer Res; 2006; 26(6B):4373-7. PubMed ID: 17201157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.